Physician profile
David Coughlin
NPI 1740543784
$20,486.44
in general payments reported to CMS, 2019-2025
16 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $357 · 2021: $59.13 · 2022: $1.18 · 2023: $149 · 2024: $563 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $563 · Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $562.50 |
| Food and Beverage | $254.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $18,750.00 | 2019 | |
| Boston Scientific Corporation | $871.16 | 2019-2025 | General - Dbs |
| Abbott Laboratories | $241.44 | 2019 | |
| Acadia Pharmaceuticals INC | $126.87 | 2019-2025 | Nuplazid |
| Ge Healthcare | $114.59 | 2019-2020 | |
| Merz North America, INC. | $100.00 | 2019 | |
| Allergan, INC. | $89.39 | 2020 | |
| Lilly USA, LLC | $48.20 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $35.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.68 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $23.45 | 2020 | |
| Kyowa Kirin, INC. | $21.51 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.99 | 2020 | |
| Sunovion Pharmaceuticals INC. | $11.14 | 2021 | |
| Travere Therapeutics, INC. | $1.18 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Coughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.